EN DE
STOCK COMPARISON

AbbVie vs Gilead Sciences: Fair Value & Quality

Both stocks run through our valuation models. Here is how AbbVie (ABBV) and Gilead Sciences (GILD) compare, as of Sep 12, 2026.

As of Sep 12, 2026, Fair Value Calculator sees Gilead Sciences as the more attractively valued of the two: AbbVie trades at $257 versus a fair value of $67.72 (-74%), while Gilead Sciences trades at $144 versus $147 (+2%).
AbbVie
ABBV · USD · Health Care
-74%
upside to fair value
overvalued
Price$257
Fair Value$67.72
Quality74/100
Gilead Sciences
GILD · USD · Health Care
+2%
upside to fair value
fairly valued
Price$144
Fair Value$147
Quality83/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

AbbVieGilead Sciences
Valuation
118.9×P/E (TTM)18.5×
7.16×P/S (TTM)5.61×
—P/B7.37×
16.8×EV/EBITDA12.3×
0.40×PEG2.14×
−73.7%Fair value upside+1.9%
2.6%Dividend yield2.1%
$6.74Dividend per share$3.19
Profitability
32%Operating margin39%
0.83×EBIT margin trend (5Y)2.41×
62%Return on equity43%
10%Return on assets13%
Growth
12%Revenue growth (YoY)4%
1.8%Avg. growth/yr (3Y)2.6%
6.0%Avg. growth/yr (5Y)3.6%
−6.5%Value creation/yr+10.5%
Balance & size
6.9×Interest coverage (EBIT/interest)11.4×
—Debt / equity0.98×
$449BMarket cap$167B
mixedGrowth qualityhealthy

Gilead Sciences leads: 3 to 11 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

AbbVieof which business quality 68 · market factors 73 Gilead Sciencesof which business quality 78 · market factors 68
ProfitabilityMargins and returns on capital today
39
77
Quality GrowthAre margins and returns improving?
58
67
CashflowEarnings quality: real cash, not paper profit
99
86
Fin. StrengthBalance sheet, leverage, solvency risk
47
64
InvestmentDisciplined investing over empire-building
100
97
Low VolatilityCalm price path (market factor)
87
87
MomentumPrice trend over the last 3–12 months (market factor)
61
55
52W MomentumDistance to the 52-week high (market factor)
79
71
Net IssuanceBuybacks instead of dilution
82
83

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyAbbViePrice $257Gilead SciencesPrice $144
DCF Models-54%below the price$117+55%above the price$222
Earnings-Based-83%below the price$42.53+1%close to the price$145
Dividend Discount-51%below the price$126-61%below the price$56.73
Multiples-71%below the price$73.45-19%below the price$116
Asset-Basedn/a-92%below the price$12.21
Growth DCF-41%below the price$151+16%above the price$167
Economic Profit-57%below the price$111-32%below the price$98.10
Growth Earnings-84%below the price$40.81+38%above the price$199
Minimum-84%below the price$40.81-92%below the price$12.21
Maximum-41%below the price$151+55%above the price$222
Median-57%below the price$111-9%close to the price$130
Geometric mean-67%below the price$84.83-32%below the price$97.83

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

AbbVie: 23 of 23 models see the stock below the current price.

Gilead Sciences: 11 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

AbbVie
Bear $39.47Fair Value $67.72Bull $98.87
$257 = current price (white tick)
Gilead Sciences
Bear $106Fair Value $147Bull $258
$144 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

AbbVie · Health Care

Quality score74 · Top 25%
Fair value upside-74% · bottom 25%

Gilead Sciences · Health Care

Quality score83 · Top 25%
Fair value upside+2% · above median

Bottom line

As of Sep 12, 2026, Fair Value Calculator sees Gilead Sciences as the more attractively valued of the two: AbbVie trades at $257 versus a fair value of $67.72 (-74%), while Gilead Sciences trades at $144 versus $147 (+2%).

Gilead Sciences has the higher quality score (83/100).

See the full analysis →
AbbVie · Gilead Sciences

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to AbbVie

AbbVie vs UnitedHealth GroupEli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupMerck & Company vs UnitedHealth Group

Related to Gilead Sciences

Gilead Sciences vs UnitedHealth GroupAstraZeneca vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAmgen vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.